NCIt definition : An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1
(CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic
agent maytansine (DM1), with potential antineoplastic activity. Upon administration,
indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization
the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly
dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing
tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated
antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role
in the regulation of cell growth, differentiation, and adhesion.;